THYROCARE TECH LTD
THYROCARE · Hospitals · NSE
₹529
Current Market Price
Fair Value (DCF)
₹501
Discount to FV
-5.3%
Updated just now
YieldIQ Score
74/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
60%
ROE
16.7%
Debt/Equity
0.05
WACC
11.1%
Market Cap
₹8,418 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
35.6%
Return on capital employed
EV / EBITDA
29.0×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
48.7×
EBIT covers interest
Current Ratio
2.77×
Short-term liquidity
Asset Turnover
1.20×
Revenue per ₹ of assets
Revenue CAGR (3Y)
16.7%
3-year revenue growth
Revenue CAGR (5Y)
10.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹528.9
Bear case
Margin of Safety -953.2%
Implied upside -90.5%
Base case
Margin of Safety -6.0%
Implied upside -5.6%
Bull case
Margin of Safety +8.7%
Implied upside +9.5%
Ratio Trends
THYROCARE · last 7 annual periods
ROE
16.7%
ROCE
35.6%
Operating Margin
—
Debt / Equity
0.05×
PE
547.8×
EV / EBITDA
52.6×
Historical Financials
THYROCARE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹589 Cr | ₹517 Cr | ₹568 Cr | ₹681 Cr | ₹822 Cr | +8.7% |
| EBITDA | ₹264 Cr | ₹130 Cr | ₹147 Cr | ₹204 Cr | ₹274 Cr | +1.0% |
| EBIT | ₹230 Cr | ₹89.8 Cr | ₹99.8 Cr | — | — | -18.9% |
| PAT | ₹176 Cr | ₹64.5 Cr | ₹70.8 Cr | ₹91.5 Cr | ₹163 Cr | -1.9% |
| EPS (diluted) | ₹33.24 | ₹12.14 | ₹13.40 | — | — | -20.3% |
| CFO | ₹113 Cr | ₹129 Cr | ₹168 Cr | ₹180 Cr | ₹213 Cr | +17.1% |
| CapEx | ₹-37.8 Cr | ₹-43.6 Cr | ₹-61.6 Cr | ₹-33.5 Cr | ₹-20.9 Cr | — |
| FCF | ₹75.6 Cr | ₹85.7 Cr | ₹106 Cr | ₹146 Cr | ₹192 Cr | +26.3% |
| Total Assets | ₹608 Cr | ₹633 Cr | ₹644 Cr | ₹693 Cr | ₹747 Cr | +5.3% |
| Total Debt | ₹20.7 Cr | ₹23.3 Cr | ₹42.3 Cr | ₹24.7 Cr | ₹50.7 Cr | +25.1% |
| Shareholders' Equity | ₹527 Cr | ₹534 Cr | ₹527 Cr | ₹547 Cr | ₹586 Cr | +2.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
THYROCARE vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 METROPOLIS METROPOLIS | — | — | Pending | 12.6% | — |
 VIJAYA Vijaya Diagnostic Centre Limited | -455.6%-82.0% upside | 33 | Data Limited | 18.1% | — |
 SYNGENE Syngene International Limited | -81.5%-44.9% upside | 46 | Above Fair Value | 6.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
14 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹31.33/sh
Last payout
2025-10-24
₹2.33
Peak payout
₹7.00
Trailing yield
1.76%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. THYROCARE TECH LTD (THYROCARE.NS) trades at 528.90 vs a model fair value of 500.71, a gap of -5.3%. Piotroski F-score: 8/9. Moat label: W...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of THYROCARE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for THYROCARE →
Compare
Head-to-head with peers
Compare THYROCARE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse THYROCARENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.